Tumor budding index and microvessel density assessment in patients with endometrial cancer: A pilot study

Kluz,Tomasz; Łoziński,Tomasz; Czekierdowska,Sylwia; Stachowicz,Norbert; Gurynowicz,Grzegorz; Chróściel,Mieczysław; Czekierdowski,Artur

doi:10.3892/ol.2020.11811

Tumor budding index and microvessel density assessment in patients with endometrial cancer: A pilot study

Authors:
- Tomasz Kluz
- Tomasz Łoziński
- Sylwia Czekierdowska
- Norbert Stachowicz
- Grzegorz Gurynowicz
- Mieczysław Chróściel
- Artur Czekierdowski
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Fryderyk Chopin University Hospital No. 1, Faculty of Medicine, Rzeszow University, 35‑055 Rzeszow, Poland, Department of Obstetrics and Gynecology, Pro‑Familia Hospital, 35‑302 Rzeszow, Poland, Department of Gynecological Oncology and Gynecology, Poznan University of Medical Sciences, 60‑535 Poznan, Poland, Division of Perinatology and Women's Diseases, Poznan University of Medical Sciences, 60‑535 Poznan, Poland, Chair and Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, 20‑081 Lublin, Poland
Published online on: July 3, 2020 https://doi.org/10.3892/ol.2020.11811
Pages: 2701-2710
Copyright: © Kluz et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to analyze the association between tumor budding index (TBI) and microvessel density (MVD) and selected clinicopathological features in female patients with endometrial cancer (EC). The present study included 137 patients, of whom 117 had endometrial endometrioid cancer and 3 had non‑endometrioid EC (NEEC). Additionally, 8 cases of simple endometrial hyperplasia and 9 cases of atypical endometrial hyperplasia were included in the present study. Patient age, menopausal status, tumor histological type, grade and International Federation of Gynecologists and Obstetricians (FIGO) clinical stage were investigated. Immunohistochemistry was utilized to detect MVD using a CD34 antibody, and a laminin‑5γ2 antibody was used for TBI assessment. In nonmalignant endometrial lesions, the TBI was significantly lower than that in patients with EC and NEEC (P=0.002). Significant differences in median TBI (MD‑TBI) were also observed between patients with low‑grade EC (MD‑TBI, 4.5) and high‑grade EC (MD‑TBI, 16.2; P=0.01). Age, body mass index and tumor FIGO stage were not indicated to be associated with the MD‑TBI. Premenopausal patients with EC had lower MD‑TBI values than postmenopausal patients (0.3 vs. 11.1; P<0.005). The median MVD‑CD34 in the study group was 19 (range, 13‑29). Significant differences in MVD‑CD34 were observed between malignant and nonmalignant endometrial lesions (P=0.01). Histological grade was markedly associated with tumor MVD‑CD34 (P=0.001). The MVD was higher in high‑grade cancer (G3; MVD‑CD34, 24.9) than in grade G1 and G2 lesions (MVD‑CD34, 14 and 18.6, respectively; P=0.01). FIGO clinical stage was not associated with MVD‑CD34 in low and high stage lesions (MD, 18.4 for FIGO stage I/II; MD, 17.6 for FIGO stage III/IV; P=0.2). High MVD was markedly associated with high MD‑TBI (P=0.0002). In conclusion, TBI could be a valuable indicator of tumor aggressiveness in patients with EC. The presence of the tumor budding phenomenon with increased MVD may have the potential to further refine clinical management decisions when endometrial malignancy is detected.

View Figures

View References

1	Torre LA, Islami F, Siegel RL, Ward EM and Jemal A: Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev. 26:444–457. 2017. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Suarez AA, Felix AS and Cohn DE: Bokhman redux: Endometrial cancer ‘types’ in the 21st century. Gynecol Oncol. 144:243–249. 2017. View Article : Google Scholar : PubMed/NCBI
4	Emons G, Beckmann MW, Schmidt D and Mallmann P; Uterus commission of the Gynecological Oncology Working Group (AGO), : New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. 75:135–136. 2015. View Article : Google Scholar : PubMed/NCBI
5	Felix AS, Yang HP, Bell DW and Sherman ME: Epidemiology of endometrial carcinoma: Etiologic importance of hormonal and metabolic influences. Adv Exp Med Biol. 943:3–46. 2017. View Article : Google Scholar : PubMed/NCBI
6	Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, et al ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group, : ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Int J Gynecol Cancer. 26:2–30. 2016. View Article : Google Scholar : PubMed/NCBI
7	Hase K, Shatney C, Johnson D, Trollope M and Vierra M: Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon Rectum. 36:627–635. 1993. View Article : Google Scholar : PubMed/NCBI
8	Ueno H, Murphy J, Jass JR, Mochizuki H and Talbot IC: Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 40:127–132. 2002. View Article : Google Scholar : PubMed/NCBI
9	Yamaguchi Y, Ishii G, Kojima M, Yoh K, Otsuka H, Otaki Y, Aokage K, Yanagi S, Nagai K, Nishiwaki Y, et al: Histopathologic features of the tumor budding in adenocarcinoma of the lung: Tumor budding as an index to predict the potential aggressiveness. J Thorac Oncol. 5:1361–1368. 2010. View Article : Google Scholar : PubMed/NCBI
10	Gujam FJ, McMillan DC, Mohammed ZM, Edwards J and Going JJ: The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. Br J Cancer. 113:1066–1074. 2015. View Article : Google Scholar : PubMed/NCBI
11	Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, El Zimaity H, Fléjou JF, Hansen TP, Hartmann A, et al: Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 30:1299–1311. 2017. View Article : Google Scholar : PubMed/NCBI
12	Park JY, Hong DG, Chong GO and Park JY: Tumor budding is a valuable diagnostic parameter in prediction of disease progression of endometrial endometrioid carcinoma. Pathol Oncol Res. 25:723–730. 2019. View Article : Google Scholar : PubMed/NCBI
13	Lugli A, Vlajnic T, Giger O, Karamitopoulou E, Patsouris ES, Peros G, Terracciano LM and Zlobec I: Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum Pathol. 42:1833–1840. 2011. View Article : Google Scholar : PubMed/NCBI
14	Grigore AD, Jolly MK, Jia D, Farach-Carson MC and Levine H: Tumor budding: The name is EMT. Partial EMT. J Clin Med. 5:E512016. View Article : Google Scholar : PubMed/NCBI
15	Gurzu S, Turdean S, Kovecsi A, Contac AO and Jung I: Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update. World J Clin Cases. 3:393–404. 2015. View Article : Google Scholar : PubMed/NCBI
16	Koyuncuoglu M, Okyay E, Saatli B, Olgan S, Akin M and Saygili U: Tumor budding and E-Cadherin expression in endometrial carcinoma: Are they prognostic factors in endometrial cancer? Gynecol Oncol. 125:208–213. 2012. View Article : Google Scholar : PubMed/NCBI
17	Hallmann R, Horn N, Selg M, Wendler O, Pausch F and Sorokin LM: Expression and function of laminins in the embryonic and mature vasculature. Physiol Rev. 85:979–1000. 2005. View Article : Google Scholar : PubMed/NCBI
18	Miyazaki K: Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion. Cancer Sci. 97:91–98. 2006. View Article : Google Scholar : PubMed/NCBI
19	Masuda R, Kijima H, Imamura N, Aruga N, Nakazato K, Oiwa K, Nakano T, Watanabe H, Ikoma Y, Tanaka M, et al: Laminin-5γ2 chain expression is associated with tumor cell invasiveness and prognosis of lung squamous cell carcinoma. Biomed Res. 33:309–317. 2012. View Article : Google Scholar : PubMed/NCBI
20	Marangon Junior H, Rocha VN, Leite CF, de Aguiar MC, Souza PE and Horta MC: Laminin-5 gamma 2 chain expression is associated with intensity of tumor budding and density of stromal myofibroblasts in oral squamous cell carcinoma. J Oral Pathol Med. 43:199–204. 2014. View Article : Google Scholar : PubMed/NCBI
21	Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 29 (Suppl 16):15–18. 2002. View Article : Google Scholar : PubMed/NCBI
22	Demir R, Yaba A and Huppertz B: Vasculogenesis and angiogenesis in the endometrium during menstrual cycle and implantation. Acta Histochem. 112:203–214. 2010. View Article : Google Scholar : PubMed/NCBI
23	Mahecha AM and Wang H: The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and −9 in angiogenesis, metastasis, and prognosis of endometrial cancer. OncoTargets Ther. 10:4617–4624. 2017. View Article : Google Scholar
24	Viallard C and Larrivée B: Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis. 20:409–426. 2017. View Article : Google Scholar : PubMed/NCBI
25	Nagy JA and Dvorak HF: Heterogeneity of the tumor vasculature: The need for new tumor blood vessel type-specific targets. Clin Exp Metastasis. 29:657–662. 2012. View Article : Google Scholar : PubMed/NCBI
26	Zalewski K, Doniec J, Baranowski W and Bidziński M: The revised FIGO staging system for uterine malignancies. Ginekol Pol. 8:778–782. 2010.
27	Czekierdowski A, Czekierdowska S, Czuba B, Cnota W, Sodowski K, Kotarski J and Zwirska-Korczala K: Microvessel density assessment in benign and malignant endometrial changes. J Physiol Pharmacol. 59 (Suppl 4):45–51. 2008.PubMed/NCBI
28	Weidner N: Tumour vascularity and proliferation: Clear evidence of a close relationship. J Pathol. 189:297–299. 1999. View Article : Google Scholar : PubMed/NCBI
29	Karamitopoulou E, Zlobec I, Kölzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K and Lugli A: Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol. 26:295–301. 2013. View Article : Google Scholar : PubMed/NCBI
30	de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, et al PORTEC study group, : Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): An open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 17:1114–1126. 2016. View Article : Google Scholar : PubMed/NCBI
31	Huang B, Cai J, Xu X, Guo S and Wang Z: High-grade tumor budding stratifies early-stage cervical cancer with recurrence risk. PLoS One. 11:e01663112016. View Article : Google Scholar : PubMed/NCBI
32	Zlobec I and Lugli A: Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget. Oncotarget. 1:651–661. 2010. View Article : Google Scholar : PubMed/NCBI
33	Mirantes C, Espinosa I, Ferrer I, Dolcet X, Prat J and Matias-Guiu X: Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Hum Pathol. 44:1973–1981. 2013. View Article : Google Scholar : PubMed/NCBI
34	Koelzer VH, Zlobec I, Berger MD, Cathomas G, Dawson H, Dirschmid K, Hädrich M, Inderbitzin D, Offner F, Puppa G, et al: Tumor budding in colorectal cancer revisited: Results of a multicenter interobserver study. Virchows Arch. 466:485–493. 2015. View Article : Google Scholar : PubMed/NCBI
35	Mazurek A and Kuć P: Angiogenesis-prognostic factor in patients with endometrial cancer. Ginekol Pol. 76:838–845. 2005.(In Polish). PubMed/NCBI
36	Almangush A, Youssef O, M. Pirinen M, Sundström J, Leivo I and Mäkitie AA: Does evaluation of tumour budding in diagnostic biopsies have a clinical relevance? A systematic review. Histopathology. 74:536–544. 2019. View Article : Google Scholar : PubMed/NCBI
37	Papa A, Zaccarelli E, Caruso D, Vici P, Benedetti Panici P and Tomao F: Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. Expert Opin Investig Drugs. 25:31–49. 2016. View Article : Google Scholar : PubMed/NCBI
38	Lheureux S and Oza AM: Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments. Eur J Cancer. 59:99–108. 2016. View Article : Google Scholar : PubMed/NCBI